RxDoctor Payments Data

Jordan Birner, PA

Physician Assistant · Hamburg, NYNPI 1972224400

Payments from drug & device makers

$8,340in general payments, 2019–2025

Across 426 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$899
  • Novo Nordisk$882
  • AbbVie$715
  • Pfizer$640
  • Amgen$412
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,340 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$18,657
Medicare patients
121
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$51,941
EliquisApixaban32$27,617
TrulicityDulaglutide24$27,004
MounjaroTirzepatide23$26,737
JardianceEmpagliflozin16$24,713
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,710
Breo ElliptaFluticasone/Vilanterol20$9,382
Pantoprazole Sodium58$8,517
Sucralfate13$5,650
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,546
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,373
Levothyroxine Sodium140$1,995
Rosuvastatin Calcium90$1,676
SynthroidLevothyroxine Sodium32$1,676
Albuterol Sulfate HfaAlbuterol Sulfate43$1,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$899$54,06665 claims
Novo NordiskOzempic$882$51,94147 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$350$29,63853 claims
PfizerEliquis$640$27,61732 claims
Boehringer IngelheimJardiance$396$24,71316 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$48$1,995140 claims
AbbVieSynthroid$715$1,67632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Hamburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →